Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of SMT-571

Trial Profile

A phase 1 study of SMT-571

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs SMT-571 (Primary)
  • Indications Gonorrhoea
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Sep 2018 According to a Summit Therapeutics media release, Up to $4.5 million of non-dilutive funding awarded by CARB-X to support the preclinical and Phase 1 clinical development of SMT-571.
    • 15 Sep 2018 New trial record
    • 05 Sep 2018 According to a Summit Therapeutics media release, the company expects to initiate this study in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top